Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04222972
Title AcceleRET Lung Study of Pralsetinib for 1L RET Fusion-positive, Metastatic NSCLC
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Blueprint Medicines Corporation
Indications

lung non-small cell carcinoma

Therapies

Carboplatin + Pembrolizumab + Pemetrexed Disodium

Pralsetinib

Cisplatin + Gemcitabine

Carboplatin + Gemcitabine

Cisplatin + Pemetrexed Disodium

Cisplatin + Pembrolizumab + Pemetrexed Disodium

Carboplatin + Pemetrexed Disodium

Age Groups: senior | adult
Covered Countries USA

Additional content available in CKB BOOST